Article
|
Open Access
Featured
-
-
Article
| Open AccessTDP-43 forms amyloid filaments with a distinct fold in type A FTLD-TDP
Cryo-electron microscopy structures and mass spectrometry analyses show that TAR DNA-binding protein 43 (TDP-43) forms amyloid filaments with a distinct fold in type A frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP) compared with TDP-43 filaments in type B FTLD-TDP and amyotrophic lateral sclerosis.
- Diana Arseni
- , Renren Chen
- & Benjamin Ryskeldi-Falcon
-
Article
| Open AccessMedin co-aggregates with vascular amyloid-β in Alzheimer’s disease
Medin promotes the formation of vascular aggregates with amyloid-β in mouse models and in human patients with Alzheimer’s disease, and is associated with vascular defects and cognitive decline.
- Jessica Wagner
- , Karoline Degenhardt
- & Jonas J. Neher
-
Article |
A mechanism for oxidative damage repair at gene regulatory elements
The nuclear mitotic apparatus protein NuMA helps to protect genes from oxidative damage by occupying regions around transcription start sites, binding DNA repair factors and promoting transcription following damage.
- Swagat Ray
- , Arwa A. Abugable
- & Sherif F. El-Khamisy
-
Article |
Somatic genomic changes in single Alzheimer’s disease neurons
Analyses of single-cell whole-genome sequencing data show that somatic mutations are increased in the brain of individuals with Alzheimer’s disease compared to neurotypical individuals, with a pattern of genomic damage distinct from that of normal ageing.
- Michael B. Miller
- , August Yue Huang
- & Christopher A. Walsh
-
Article |
Structure of pathological TDP-43 filaments from ALS with FTLD
Cryo-electron microscopy of aggregated TDP-43 from postmortem brain tissue of individuals who had ALS with FTLD reveals a filament structure with distinct features to other neuropathological protein filaments, such as those of tau and α-synuclein.
- Diana Arseni
- , Masato Hasegawa
- & Benjamin Ryskeldi-Falcon
-
Article |
C9orf72 suppresses systemic and neural inflammation induced by gut bacteria
Reduced abundance of immune-stimulating gut bacteria ameliorated the inflammatory and autoimmune phenotypes of mice with mutations in C9orf72, which in the human orthologue are linked to amyotrophic lateral sclerosis and frontotemporal dementia.
- Aaron Burberry
- , Michael F. Wells
- & Kevin Eggan
-
Article |
APOE4 leads to blood–brain barrier dysfunction predicting cognitive decline
Breakdown of the blood–brain barrier in individuals carrying the ε4 allele of the APOE gene, but not the ε3 allele, increases with and predicts cognitive impairment and is independent of amyloid β or tau pathology.
- Axel Montagne
- , Daniel A. Nation
- & Berislav V. Zlokovic
-
Article |
NLRP3 inflammasome activation drives tau pathology
The authors show that NLRP3 inflammasome is activated in microglia of patients with fronto-temporal dementia and in a mouse model of tau pathology, and that the loss of NLRP3 inflammasome function decreases tau pathology and improves cognition in mice.
- Christina Ising
- , Carmen Venegas
- & Michael T. Heneka
-
Letter |
Novel tau filament fold in chronic traumatic encephalopathy encloses hydrophobic molecules
Cryo-electron microscopy structures of tau filaments from the brains of three individuals with chronic traumatic encephalopathy reveal distinct assembled tau conformers, with a novel protofilament fold enclosing hydrophobic molecules.
- Benjamin Falcon
- , Jasenko Zivanov
- & Sjors H. W. Scheres
-
Letter |
Structures of filaments from Pick’s disease reveal a novel tau protein fold
The structures of tau filaments from patients with the neurodegenerative disorder Pick’s disease show that the filament fold is different from that of the tau filaments found in Alzheimer’s disease.
- Benjamin Falcon
- , Wenjuan Zhang
- & Michel Goedert
-
Letter |
High performance plasma amyloid-β biomarkers for Alzheimer’s disease
Measurement of human plasma amyloid-β biomarkers using immunoprecipitation coupled with mass spectrometry reliably predicts individual brain amyloid-β status and has potential clinical utility.
- Akinori Nakamura
- , Naoki Kaneko
- & Katsuhiko Yanagisawa
-
Letter |
Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice
A decrease in ataxin-2 levels leads to a reduction in the aggregation of TDP-43, markedly increased lifespan and improved motor function in a transgenic mouse model of TDP-43 proteinopathy.
- Lindsay A. Becker
- , Brenda Huang
- & Aaron D. Gitler
-
Article |
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Aducanumab, a human monoclonal antibody that selectively targets aggregated Aβ, reduces soluble and insoluble Aβ in the brain, an action accompanied by a dose-dependent slowing of clinical decline in treated patients.
- Jeff Sevigny
- , Ping Chiao
- & Alfred Sandrock
-
Brief Communications Arising |
Collinge et al. reply
- John Collinge
- , Zane Jaunmuktane
- & Sebastian Brandner
-
Letter |
Evidence for human transmission of amyloid-β pathology and cerebral amyloid angiopathy
Treatment of children with human cadaver-derived growth hormone (c-hGH) contaminated with prions resulted in transmission of Creutzfeldt–Jakob disease (CJD); unexpectedly, in an autopsy study of eight such iCJD patients, the authors found amyloid-β deposition in the grey matter typical of that seen in Alzheimer's disease and amyloid-β in the blood vessel walls characteristic of cerebral amyloid angiopathy, consistent with iatrogenic transmission of amyloid-β pathology in addition to CJD and suggests that healthy c-hGH-exposed individuals may also be at risk of Alzheimer's disease and cerebral amyloid angiopathy.
- Zane Jaunmuktane
- , Simon Mead
- & Sebastian Brandner
-
Brief Communications Arising |
PLD3 gene variants and Alzheimer's disease
- Basavaraj V. Hooli
- , Christina M. Lill
- & Rudolph E. Tanzi
-
-
Letter |
Rare coding variants in the phospholipase D3 gene confer risk for Alzheimer’s disease
Whole-exome sequencing reveals that a rare variant of phospholipase D3 (PLD3(V232M)) segregates with Alzheimer’s disease status in two independent families and doubles risk for the disease in case–control series, and that several other PLD3 variants increase risk for Alzheimer’s disease in African Americans and people of European descent.
- Carlos Cruchaga
- , Celeste M. Karch
- & Alison M. Goate
-
Letter |
NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice
Alzheimer’s-prone mice deficient in NLRP3 or caspase-1 fail to develop learning deficits and show reduced neuropathology.
- Michael T. Heneka
- , Markus P. Kummer
- & Douglas T. Golenbock
-
News |
Alzheimer's 'in a dish' shows promise
Reprogrammed cells suggest path towards early diagnosis and drug development.
- Ewen Callaway
-
News Q&A |
Fleshing out the US Alzheimer’s strategy
Researchers aim to be able to treat and delay onset of the disease by 2020.
- Meredith Wadman
-
Brief Communications Arising |
Phiel et al. reply
- Christopher J. Phiel
- , Christina A. Wilson
- & Peter S. Klein
-
Brief Communications Arising |
GSK-3α/β kinases and amyloid production in vivo
- Tomasz Jaworski
- , Ilse Dewachter
- & Fred Van Leuven
-
News |
Lessons about Alzheimer's disease
Psychologist Margaret Gatz explains what 25 years of research have taught her about reducing the risk of dementia.
- Gwyneth Dickey Zakaib
-
Outlook |
Dementia: A problem for our age
As the number of Alzheimer's cases rises rapidly in an ageing global population, the need to understand this puzzling disease is growing.
- Alison Abbott
-
Outlook |
Perspective: Prevention is better than cure
Attempts to reduce amyloid-β in the brain have yet to show clinical benefits. Starting treatment early is the best hope, says Sam Gandy
- Sam Gandy
-
-
News |
Alzheimer's-disease probe nears approval
Imaging technique could help to resolve questions about brain plaques associated with the condition.
- Heidi Ledford
-
News & Views |
Recollection of lost memories
With age comes wisdom, or so they say. The reality is that, with age, the ability to store memories declines. One way of tackling this problem might be to raise neuronal levels of the signalling molecule EphB2. See Article p.47
- Robert C. Malenka
- & Roberto Malinow